View ValuationSilo Wellness 将来の成長Future 基準チェック /06現在、 Silo Wellnessの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長32.4%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesBoard Change • Mar 07High number of new directorsCOO & Director Michael Hartman was the last director to join the board, commencing their role in 2022.お知らせ • Aug 30+ 1 more updateSilo Wellness Inc. announced that it expects to receive CAD 0.25 million in fundingSilo Wellness Inc. announced a best-efforts private placement to issue 12,500,000 common shares at a price of CAD 0.02 per share for the gross proceeds of CAD 250,000 on August 29, 2023.Reported Earnings • Jun 28Second quarter 2023 earnings released: EPS: US$0.028 (vs US$0.32 loss in 2Q 2022)Second quarter 2023 results: EPS: US$0.028 (up from US$0.32 loss in 2Q 2022). Revenue: US$79.2k (down 26% from 2Q 2022). Net income: US$3.03m (up US$4.27m from 2Q 2022).Board Change • Apr 11High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Founder, Interim CEO, President & Chairman Mike Arnold is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Feb 18Silo Wellness Inc. Announces Resignation of Gerard Lee from as A Director of the BoardSilo Wellness Inc. accepted the resignation of Gerard Lee from his position as a director of the board, effective immediately. The board of directors includes Greg Biniowsky (independent director), Vancouver lawyer; Simon Bababeygy, M.D. (independent director), California physician; Michael Hartman, California pharmaceutical chemist; and Mike Arnold, Oregon lawyer.Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Founder, Interim CEO, President & Chairman Mike Arnold is the most experienced director on the board, commencing their role in 2021. Independent Director Gregory Biniowsky was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • Sep 28Third quarter 2022 earnings released: US$0.42 loss per share (vs US$0.38 loss in 3Q 2021)Third quarter 2022 results: US$0.42 loss per share (further deteriorated from US$0.38 loss in 3Q 2021). Revenue: US$85.3k (up US$71.5k from 3Q 2021). Net loss: US$1.72m (loss widened 45% from 3Q 2021).Reported Earnings • Jul 01Second quarter 2022 earnings released: US$0.32 loss per share (vs US$1.28 loss in 2Q 2021)Second quarter 2022 results: US$0.32 loss per share (up from US$1.28 loss in 2Q 2021). Revenue: US$107.4k (up 254% from 2Q 2021). Net loss: US$1.24m (loss narrowed 64% from 2Q 2021).Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. CEO & Director Douglas Gordon was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Director Overboarding • Aug 17Director Wayne Isaacs has joined 4th company boardDirector Wayne Isaacs has been appointed to the board of ZEB Nickel Corp. (TSXV:ZBNI). Isaacs now sits on a total of 4 company boards. With 4 board positions including the role of CEO at ZEB Nickel Corp. (TSXV:ZBNI), the director is at risk of having too many board obligations according to the Simply Wall St Risk Model.Executive Departure • Apr 01Director has left the companyOn the 26th of March, Maurice Colson's tenure in the role of Director ended. We don't have any record of a personal shareholding under Maurice's name. Maurice is the only executive to leave the company over the last 12 months.お知らせ • Mar 13FlyOverture Equity, Inc. Announces Resignation of Fred Leigh from the Board of DirectorsFlyOverture Equity, Inc. reports that Fred Leigh has resigned from the board of directors of the Company. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Silo Wellness は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測CNSX:SILO - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数7/31/20230100N/A4/30/20230-100N/A1/31/20230-500N/A10/31/20220-6-1-1N/A7/31/20220-5-1-1N/A4/30/20220-4-2-2N/A1/31/20220-7-4-4N/A10/31/20210-6-4-4N/A7/31/20210-5-4-4N/A4/30/20210-5-3-3N/A1/31/20210-1-1-1N/A10/31/20200-1-1-1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: SILOの予測収益成長が 貯蓄率 ( 2.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: SILOの収益がCanadian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: SILOの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: SILOの収益がCanadian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: SILOの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: SILOの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/06/03 12:06終値2024/03/06 00:00収益2023/07/31年間収益2022/10/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Silo Wellness Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • Mar 07High number of new directorsCOO & Director Michael Hartman was the last director to join the board, commencing their role in 2022.
お知らせ • Aug 30+ 1 more updateSilo Wellness Inc. announced that it expects to receive CAD 0.25 million in fundingSilo Wellness Inc. announced a best-efforts private placement to issue 12,500,000 common shares at a price of CAD 0.02 per share for the gross proceeds of CAD 250,000 on August 29, 2023.
Reported Earnings • Jun 28Second quarter 2023 earnings released: EPS: US$0.028 (vs US$0.32 loss in 2Q 2022)Second quarter 2023 results: EPS: US$0.028 (up from US$0.32 loss in 2Q 2022). Revenue: US$79.2k (down 26% from 2Q 2022). Net income: US$3.03m (up US$4.27m from 2Q 2022).
Board Change • Apr 11High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Founder, Interim CEO, President & Chairman Mike Arnold is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Feb 18Silo Wellness Inc. Announces Resignation of Gerard Lee from as A Director of the BoardSilo Wellness Inc. accepted the resignation of Gerard Lee from his position as a director of the board, effective immediately. The board of directors includes Greg Biniowsky (independent director), Vancouver lawyer; Simon Bababeygy, M.D. (independent director), California physician; Michael Hartman, California pharmaceutical chemist; and Mike Arnold, Oregon lawyer.
Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Founder, Interim CEO, President & Chairman Mike Arnold is the most experienced director on the board, commencing their role in 2021. Independent Director Gregory Biniowsky was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • Sep 28Third quarter 2022 earnings released: US$0.42 loss per share (vs US$0.38 loss in 3Q 2021)Third quarter 2022 results: US$0.42 loss per share (further deteriorated from US$0.38 loss in 3Q 2021). Revenue: US$85.3k (up US$71.5k from 3Q 2021). Net loss: US$1.72m (loss widened 45% from 3Q 2021).
Reported Earnings • Jul 01Second quarter 2022 earnings released: US$0.32 loss per share (vs US$1.28 loss in 2Q 2021)Second quarter 2022 results: US$0.32 loss per share (up from US$1.28 loss in 2Q 2021). Revenue: US$107.4k (up 254% from 2Q 2021). Net loss: US$1.24m (loss narrowed 64% from 2Q 2021).
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. CEO & Director Douglas Gordon was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Director Overboarding • Aug 17Director Wayne Isaacs has joined 4th company boardDirector Wayne Isaacs has been appointed to the board of ZEB Nickel Corp. (TSXV:ZBNI). Isaacs now sits on a total of 4 company boards. With 4 board positions including the role of CEO at ZEB Nickel Corp. (TSXV:ZBNI), the director is at risk of having too many board obligations according to the Simply Wall St Risk Model.
Executive Departure • Apr 01Director has left the companyOn the 26th of March, Maurice Colson's tenure in the role of Director ended. We don't have any record of a personal shareholding under Maurice's name. Maurice is the only executive to leave the company over the last 12 months.
お知らせ • Mar 13FlyOverture Equity, Inc. Announces Resignation of Fred Leigh from the Board of DirectorsFlyOverture Equity, Inc. reports that Fred Leigh has resigned from the board of directors of the Company.